What MBX Biosciences MBX capital allocation tells us MBX Biosciences Beats Estimates by 20 as Losses Persist Keros Therapeutics KROS Stock Technical Risk Signals Q4 2025 EPS Misses Views GROW US reports Q3 2025 EPS of negative 003 as shares rise 076 percent with no analyst consensus estimates KNDI Kandi revenue tumbles 315 percent as demand weakens shares slide 4 percent